Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:abusePotential |
moderate
|
| gptkbp:activeIngredient |
gptkb:difenoxin
atropine |
| gptkbp:associatedWith |
gptkb:Lomotil
gptkb:Imodium |
| gptkbp:ATCCode |
A07DA52
|
| gptkbp:contains |
gptkb:atropine_sulfate
gptkb:difenoxin_hydrochloride |
| gptkbp:contraindication |
jaundice
children under 12 infectious diarrhea obstructive jaundice |
| gptkbp:controlledSubstanceSchedule |
Schedule IV (US)
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Motofen
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
opioid receptor agonist
anticholinergic |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness dry mouth |
| gptkbp:soldIn |
gptkb:Canada
gptkb:Europe |
| gptkbp:status |
FDA approved
|
| gptkbp:usedFor |
diarrhea
|
| gptkbp:bfsParent |
gptkb:Schedule_V
gptkb:Schedule_V_(US) |
| gptkbp:bfsLayer |
6
|